CLINICAL_TRIALS trial_result · 2019-07-30

Clinical Trial Update: SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC) [Phase 2]

Phase 2 study of SGI-110 (guadecitabine) in advanced hepatocellular carcinoma was completed and its results were posted on 2019-07-30.

Upgrade for the full analysis, importance score, and drug timeline.

Sponsor: Astex Pharmaceuticals, Inc. | Conditions: Hepatocellular Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2019-07-30